Why Isn't There Routine Prenatal Screening for FNAIT?

If your baby suffered a serious complication from Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), it is completely natural to wonder—and be frustrated—that your doctor did not test you for this condition during your routine pregnancy bloodwork. Currently, there is no universal prenatal screening program for FNAIT. Instead, the medical system typically only tests for it after a family has already had an affected child (or if there is a known close family history, such as a sister who had a baby with FNAIT) ^[1]. Because of this, the first baby in a family is often unexpectedly affected before anyone knows the mother is at risk.

While FNAIT can cause severe complications like brain bleeds (intracranial hemorrhage), major medical organizations have not yet endorsed universal screening. The debate centers on three major challenges: the rarity of the condition, the intensity of current treatments, and the high rate of “overtreatment” and anxiety for mothers who may not actually need intervention.

The Medical Debate Against Universal Screening

1. The Challenge of “Overtreatment” and Anxiety

One of the biggest hurdles to universal screening is predicting exactly which babies will get sick. The screening itself would involve a simple blood test to check the mother’s platelet type and look for specific HPA antibodies ^[2]. However, many women who test positive for these antibodies will go on to deliver perfectly healthy babies whose platelet levels never drop to dangerous levels ^[3]. If every pregnant person were screened, thousands would receive a terrifying “high risk” result, causing immense psychological stress and anxiety for what might ultimately be a false alarm or a very mild case.

2. Intense and Expensive Treatments

If a screening test indicates a mother is at high risk, the standard preventative treatment is intravenous immunoglobulin (IVIG)—a therapy made of healthy antibodies from donated blood ^[4]. This therapy is highly demanding: it usually requires time-consuming IV infusions every week throughout the pregnancy, and it comes with heavy physical side effects for the mother as well as significant financial costs ^[5][3]. Because doctors cannot easily tell which “at-risk” pregnancies will result in serious complications, a universal screening program would mean subjecting many healthy pregnancies to these intense and burdensome treatments unnecessarily ^[3].

3. Rarity and Health System Costs

From a public health perspective, national screening programs are evaluated on their overall cost-effectiveness. FNAIT itself is estimated to occur in about 10 to 20 out of every 10,000 pregnancies, but severe bleeding (like a brain bleed) is even rarer, affecting roughly 1 in 10,000 pregnancies without intervention ^[6]. Because of this statistical rarity, creating a nationwide program to test millions of pregnant women—and treating everyone who tests positive with expensive IVIG therapies—is currently viewed by many health systems as economically prohibitive ^[5][7].

While it is difficult to hear that preventing brain bleeds is considered “too expensive” because they are rare on a spreadsheet, the devastation is total for the families who experience it. This cost-benefit analysis often leaves parents feeling as though their baby’s safety was sacrificed to save the health system money.

What This Means For Your Future

If you have already had a baby diagnosed with FNAIT, you are no longer in the “general population” category. For any future pregnancies, your care will be entirely different. Your doctor will likely use targeted screening and monitoring, and you will be a candidate for preventative treatments like IVIG to protect your next baby from the start ^[1][8].

The Push for Change

The current guidelines are not set in stone, and the landscape is shifting. Many families who have experienced this trauma feel strongly that the “wait and see” approach is unacceptable.

• Patient Advocacy: Groups like NaitBabies, a charitable organization run by families affected by the disease, are actively fighting to change prenatal guidelines ^[9]. They argue that the true incidence of FNAIT is higher than widely recognized because it is frequently under-diagnosed or missed entirely ^[10][11].
• Medical Advancements: Researchers have proven that early screening for FNAIT risk is technically possible in the first trimester, and pilot screening programs have been explored in several European countries to test how this could work in the real world ^[2][12]. At the same time, clinical trials are investigating new, targeted therapies, such as a medication called nipocalimab (a drug that blocks certain antibodies from crossing the placenta) ^[13][14]. If easier, more targeted, and less burdensome treatments become available, the arguments against universal screening may dissolve, paving the way for routine testing in the future.